Immunity after yellow fever vaccination in HIV positive travelers - YELLAR study

Immunity after yellow fever vaccination in HIV positive travelers - YELLAR study - YELLAR study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39974

Enrollment

Registered

2012-08-02

Start date

2013-06-08

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yellow Fever Infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: > 18 years Indication for first yellow fever vaccination Travel to a yellow fever endemic area within one year Stable CD4 counts between 200 and 500 for at least two one year (2 measurements at half yearly clinical visits) and certain travel to yellow fever endemic area, even if travel has not been planned.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The height and duration of viraemia, the seroconversion rate and the level of neutralising antibodies in relation to: - the actual number of CD4 positive cells - the nadir of CD4 positive cells - the duration of CD4 count above 200 - and the viral load of HIV	—

Secondary

Measure	Time frame
Local and systemic side effects of yellow fever vaccination in HIV positive patients. A comparison of all endpoints in the HIV positive group compared to the healthy controls.	—

Countries

Netherlands

Outcome results